Fielder Capital Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Fielder Capital Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$221K	Sell	354 -144	-29%	-$98K	0.05%	272
2026 Q1	$385K	Buy	498 +47	+10%	+$36K	0.08%	161
2025 Q4	$348K	Buy	451 +67	+17%	+$45.5K	0.07%	162
2025 Q3	$216K	Buy	+384	New	+$217K	0.05%	239
2024 Q4	–	Sell	-263	Closed	-$276K	–	228
2024 Q3	$276K	Sell	263 -1	-0.4%	-$1.11K	0.09%	144
2024 Q2	$277K	Buy	264 +4	+2%	+$3.88K	0.11%	130
2024 Q1	$250K	Sell	260 -4	-2%	-$3.8K	0.11%	128
2023 Q4	$232K	Buy	+264	New	+$217K	0.14%	119

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Fielder Capital Group's REGN Position: Q2 2026 in Review

Fielder Capital Group reduced its Regeneron Pharmaceuticals (REGN) stake by 29% in Q2 2026, selling an estimated $98K and leaving 354 shares worth $221K. The position accounts for 0.05% of the portfolio, ranked #272.

Fielder Capital Group first reported a position in REGN in Q4 2023 and has held it in 8 quarters since. The position peaked at $385K in Q1 2026. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Fielder Capital Group held 354 shares of Regeneron Pharmaceuticals worth $221K as of Q2 2026.
Fielder Capital Group sold 144 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $98K.
Regeneron Pharmaceuticals made up 0.05% of Fielder Capital Group's portfolio in Q2 2026, its #272 holding.
Fielder Capital Group first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
Fielder Capital Group's Regeneron Pharmaceuticals position peaked at $385K in Q1 2026.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Fielder Capital Group's 13F filing for Q2 2026, filed 6 Aug 2026.